AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3396674 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 18
Study 29426926 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantum clique gossiping using local clique operations in networks of interconnected qubits
Number of subjects: 0
Study 29426926 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantum clique gossiping
Number of subjects: 0
Study 29426926 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger quantum cliques
Number of subjects: 0
Study 28762606 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer-guided warfarin therapy (low intensity adjusted to standard intensity based on D-dimer levels)
Number of subjects: 718
Study 28762606 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer-guided warfarin therapy
Number of subjects: 718
Study 28762606 — intervention group
Group type: COMPARATOR
Intervention: Standard intensity warfarin therapy (INR 2.5-3.5)
Number of subjects: 718
Study 28762606 — intervention group
Group type: COMPARATOR
Intervention: Low intensity warfarin therapy (INR 1.8-2.6)
Number of subjects: 718
Study 26258147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon tea
Number of subjects: 0
Study 26258147 — intervention group
Group type: COMPARATOR
Intervention: Control (without cinnamon tea)
Number of subjects: 0
Study 23540641 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated wires from Ortho Organizers
Number of subjects: 4
Study 23540641 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated wires from Trianeiro
Number of subjects: 4
Study 23540641 — intervention group
Group type: COMPARATOR
Intervention: Coated wires from TP Orthodontics
Number of subjects: 4
Study 23540641 — intervention group
Group type: COMPARATOR
Intervention: Coated wires from Orthometric
Number of subjects: 4
Study 21539614 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed cow's milk formula (phCMF)
Number of subjects: 113
Study 21539614 — intervention group
Group type: COMPARATOR
Intervention: Conventional cow's milk formula (CMF)
Number of subjects: 113
Study 18004611 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake among women using depot medroxyprogesterone acetate (DMPA)
Number of subjects: 625
Study 18004611 — intervention group
Group type: COMPARATOR
Intervention: Caffeine intake among the general population of young women
Number of subjects: 625
Study 16531173 — intervention group
Group type: EXPERIMENTAL
Intervention: Reality female condom (FC1)
Number of subjects: 276
Study 16531173 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic latex prototype (FC2)
Number of subjects: 276
Study 14555563 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 20
Study 14555563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11094003 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine at 10 mL/h via a disposable infusion pump
Number of subjects: 40
Study 11094003 — intervention group
Group type: COMPARATOR
Intervention: Normal saline at 10 mL/h via a disposable infusion pump
Number of subjects: 40
Study 8882996 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking 3 d.wk‐1 (N = 19)
Number of subjects: 79
Study 8882996 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking 5 d.wk‐1 (N = 17)
Number of subjects: 79
Study 8882996 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (Control group, N = 20)
Number of subjects: 79
Study 8054250 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg rac-ibuprofen
Number of subjects: 18
Study 8054250 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg rac-ibuprofen
Number of subjects: 18
Study 8054250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3047100 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg nightly for 5 weeks
Number of subjects: 0
Study 3047100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31994303 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 mg ferrous sulfate twice a day (total elemental iron dose: 160 mg / day)
Number of subjects: 0
Study 31994303 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 mg ferrous sulfate once a day (total elemental iron dose: 80 mg / day)
Number of subjects: 0
Study 31994303 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 mg ferrous sulfate every other day (total elemental iron dose: 80 mg / every other day)
Number of subjects: 0
Study 27048306 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 411
Study 27048306 — intervention group
Group type: COMPARATOR
Intervention: Stress Testing
Number of subjects: 411
Study 25922062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mito-FLAG with Ara-C as bolus (1000 mg/m(2) over 1 h, every 12 h, days 1-5)
Number of subjects: 252
Study 25922062 — intervention group
Group type: COMPARATOR
Intervention: Mito-FLAG with Ara-C as continuous infusion (150 mg/m(2) over 24 h, days 1-5)
Number of subjects: 252
Study 25922062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mito-FLAG with Ara-C as bolus
Number of subjects: 252
Study 25922062 — intervention group
Group type: COMPARATOR
Intervention: Mito-FLAG with Ara-C as continuous infusion
Number of subjects: 252
Study 23827771 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone + Essex® cream
Number of subjects: 104
Study 23827771 — intervention group
Group type: COMPARATOR
Intervention: Essex® cream
Number of subjects: 104
Study 23827771 — intervention group
Group type: COMPARATOR
Intervention: Canoderm® cream
Number of subjects: 104
Study 21062464 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT oral dose tailored by DNA analysis (OPRM1 gene) (genotype)
Number of subjects: 630
Study 21062464 — intervention group
Group type: COMPARATOR
Intervention: NRT oral dose tailored by nicotine dependence questionnaire score (phenotype)
Number of subjects: 630
Study 18476606 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-PSN 1.0 mg twice a week for two months
Number of subjects: 60
Study 18476606 — intervention group
Group type: COMPARATOR
Intervention: Intranasal azelastine twice a day as needed
Number of subjects: 60
Study 17182361 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador therapy (mistletoe preparation)
Number of subjects: 197
Study 14658986 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term pharmacotherapy
Number of subjects: 0
Study 14658986 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (alone or combined with medication)
Number of subjects: 0
Study 14658986 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10714729 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone Maintenance Therapy (MMT)
Number of subjects: 179
Study 10714729 — intervention group
Group type: COMPARATOR
Intervention: Detoxification
Number of subjects: 179
Study 10714729 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 179
Study 8704662 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized planned care for patients and regular clinical systematic supervision for nurses on the experimental ward (EW)
Number of subjects: 107
Study 8704662 — intervention group
Group type: COMPARATOR
Intervention: No changes made on the control ward (CW)
Number of subjects: 107
Study 8704662 — intervention group
Group type: EXPERIMENTAL
Intervention: Surviving patients in the experimental ward (EW)
Number of subjects: 107
Study 8704662 — intervention group
Group type: COMPARATOR
Intervention: Surviving patients in the control ward (CW)
Number of subjects: 107
Study 1431251 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccines
Number of subjects: 646
Study 6697786 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glycopyrrolate (1.3 mg)
Number of subjects: 6
Study 6697786 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (2.6 mg)
Number of subjects: 6
Study 6697786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31525242 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with at least secondary level of formal education
Number of subjects: 302
Study 31525242 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers whose first pregnancy occurred between the ages of 20‐24 years
Number of subjects: 302
Study 31525242 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers who had completed at least four ANC visits
Number of subjects: 302
Study 31525242 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers who had completed three PNC visits
Number of subjects: 302
Study 31525242 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers whose nearest health facility was less than one hour walking distance (30‐59 minutes)
Number of subjects: 302
Study 31525242 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers whose household monthly income was more than $100
Number of subjects: 302
Study 31525242 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with adequate newborn care knowledge
Number of subjects: 302
Study 29409494 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine Zengru Gao
Number of subjects: 588
Study 29409494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Zengru Gao)
Number of subjects: 588
Study 27045034 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide (oral retinoid) for 2 years
Number of subjects: 99
Study 27045034 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline VEGF levels in the top quintile (≥350 pg/mL)
Number of subjects: 99
Study 27045034 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA aneuploidy in bladder washing
Number of subjects: 99
Study 24578135 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralization of Dkk1 using a monoclonal antibody after renal injury
Number of subjects: 0
Study 24578135 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate binder therapy
Number of subjects: 0
Study 24578135 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Dkk1 antibody and phosphate binder therapy
Number of subjects: 0
Study 22925537 — intervention group
Group type: EXPERIMENTAL
Intervention: 40,000 IU vitamin D (cholecalciferol) per week
Number of subjects: 332
Study 22925537 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IU vitamin D per week
Number of subjects: 332
Study 22925537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study 20205105 — intervention group
Group type: COMPARATOR
Intervention: (131)I and thiamazole
Number of subjects: 200
Study 20205105 — intervention group
Group type: COMPARATOR
Intervention: (131)I and lithium carbonate
Number of subjects: 200
Study 20205105 — intervention group
Group type: COMPARATOR
Intervention: (131)I only (150-200 Gy)
Number of subjects: 200
Study 20205105 — intervention group
Group type: COMPARATOR
Intervention: (131)I and prednisone
Number of subjects: 200
Study 20205105 — intervention group
Group type: COMPARATOR
Intervention: (131)I only (250-350 Gy)
Number of subjects: 200
Study 17396552 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA technology (experimental group)
Number of subjects: 0
Study 17396552 — intervention group
Group type: COMPARATOR
Intervention: Textbook (control group)
Number of subjects: 0
Study 16215448 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 220
Study 16215448 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 220
Study 16215448 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 220
Study 16215448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 16215448 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 220
Study 16215448 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management plus psychological intervention
Number of subjects: 220
Study 12208481 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1431
Study 12208481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1431
Study 12208481 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (CC genotype)
Number of subjects: 1431
Study 12208481 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (CT genotype)
Number of subjects: 1431
Study 12208481 — intervention group
Group type: COMPARATOR
Intervention: Placebo (reference group)
Number of subjects: 1431
Study 12208481 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FXIIa levels
Number of subjects: 1431
Study 10206198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulation induction (clomiphene, hMG)
Number of subjects: 128
Study 10206198 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (no further treatment)
Number of subjects: 128
Study 10206198 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 128
Study 10206198 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 128
Study 10206198 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG
Number of subjects: 128
Study 7500752 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose traction
Number of subjects: 151
Study 7500752 — intervention group
Group type: COMPARATOR
Intervention: Sham traction
Number of subjects: 151
Study 2217010 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of thiopentone and etomidate (5:1 ratio)
Number of subjects: 0
Study 2217010 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of thiopentone and etomidate (13:1 ratio)
Number of subjects: 0
Study 2217010 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of thiopentone and etomidate (25:1 ratio)
Number of subjects: 0
Study 2217010 — intervention group
Group type: COMPARATOR
Intervention: Etomidate alone
Number of subjects: 0
Study 2217010 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone alone
Number of subjects: 0
Study 6994960 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin therapy
Number of subjects: 0
Study 6994960 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what treatment was used)
Number of subjects: 0
Study 31220775 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD implantation with DFT
Number of subjects: 965
Study 31220775 — intervention group
Group type: COMPARATOR
Intervention: S-ICD implantation without DFT (with PRAETORIAN score evaluation)
Number of subjects: 965
Study 27801706 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT)
Number of subjects: 21711
Study 27801706 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium + Vitamin D (Ca/D)
Number of subjects: 21711
Study 27801706 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy + Calcium + Vitamin D (HT + Ca/D)
Number of subjects: 21711
Study 25874723 — intervention group
Group type: COMPARATOR
Intervention: HIV-DNA vaccine containing plasmids expressing HIV-1 gp160 subtypes A, B, C, Rev B, Gag A, B and RTmut B, followed by recombinant HIV-MVA boost expressing CRF01_AE HIV-1 Env subtype E and Gag-Pol subtype A.
Number of subjects: 0
Study 23329203 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbations at varying bandwidths (0.3 Hz to 8.0 Hz) with eyes open
Number of subjects: 0
Study 23329203 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbations at varying bandwidths (0.3 Hz to 8.0 Hz) with eyes closed
Number of subjects: 0
Study 23329203 — intervention group
Group type: COMPARATOR
Intervention: Comparison of reflexes with eyes open vs. eyes closed
Number of subjects: 0
Study 20650570 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory stress (LS; public speaking)
Number of subjects: 34
Study 20650570 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated emergency situation (SIM; myocardial ischemia and ventricular fibrillation)
Number of subjects: 34
Study 20650570 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 34
Study 19622191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk (FM) containing Bifidobacterium lactis DN-173 010 and yoghurt strains
Number of subjects: 197
Study 19622191 — intervention group
Group type: COMPARATOR
Intervention: Control non-fermented dairy product
Number of subjects: 197
Study 16418018 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg 1 hour before surgery, then 200 mg every 12 hours for the first 5 days
Number of subjects: 80
Study 16418018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15590524 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminal tarsal rotation (n = 30)
Number of subjects: 90
Study 15590524 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarsal rotation with tarso‐conjunctival advancement (n = 30)
Number of subjects: 90
Study 15590524 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior lamellar repositioning with lid margin split and wedge resection of tarsus (n = 30)
Number of subjects: 90
Study 15590524 — intervention group
Group type: COMPARATOR
Intervention: All procedures
Number of subjects: 90
Study 11668377 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical block anesthesia
Number of subjects: 401
Study 11668377 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 401
Study 9211578 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine (5 g)
Number of subjects: 8
Study 9211578 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 g lactose)
Number of subjects: 8
Study 8433254 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline HCl 50 mg/ml
Number of subjects: 50
Study 8433254 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline HCl 10 mg/ml
Number of subjects: 50
Study 8433254 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate
Number of subjects: 50
Study 8433254 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% sterile saline)
Number of subjects: 50
Study 2954215 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electrical stimulation
Number of subjects: 117
Study 2954215 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercises
Number of subjects: 117
Study 2954215 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-high-frequency electrical stimulation
Number of subjects: 117
Study 2954215 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 28892591 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 10 mg once-weekly
Number of subjects: 61
Study 28892591 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice-weekly
Number of subjects: 61
Study 28892591 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 10 mg twice-weekly
Number of subjects: 61
Study 28892591 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg every 2 weeks
Number of subjects: 61
Study 28892591 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once-weekly
Number of subjects: 61
Study 27660305 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound-guided ultrafiltration prescription policy
Number of subjects: 79
Study 27660305 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 79
Study 25068411 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 3 mg/kg plus ketamine 50 mg
Number of subjects: 40
Study 25068411 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 3 mg/kg
Number of subjects: 40
Study 22520536 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg and Ezetimibe 10 mg
Number of subjects: 1421
Study 22520536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1421
Study 22520536 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1421
Study 22520536 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular mass index
Number of subjects: 1421
Study 22520536 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset AF
Number of subjects: 1421
Study 20737642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate immediate release (IR) tablet formulations
Number of subjects: 0
Study 20737642 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulations containing sodium lauryl sulfate (SLS)
Number of subjects: 0
Study 18034777 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan 40 mg/day
Number of subjects: 56
Study 18034777 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan 80 mg/day
Number of subjects: 56
Study 18034777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 17154775 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-process random-walk model
Number of subjects: 0
Study 17154775 — intervention group
Group type: COMPARATOR
Intervention: Hybrid 2-stage model
Number of subjects: 0
Study 15071273 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable defibrillator (ICD)
Number of subjects: 0
Study 15071273 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 0
Study 11074199 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stent
Number of subjects: 48
Study 11074199 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 48
Study 9196650 — intervention group
Group type: EXPERIMENTAL
Intervention: Health educational leaflet
Number of subjects: 1571
Study 9196650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 1571
Study 1331992 — intervention group
Group type: EXPERIMENTAL
Intervention: lomefloxacin 400 mg
Number of subjects: 18
Study 1331992 — intervention group
Group type: EXPERIMENTAL
Intervention: ciprofloxacin 750 mg
Number of subjects: 18
Study 1331992 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 2938551 — intervention group
Group type: COMPARATOR
Intervention: Implantable pump only (Group A)
Number of subjects: 27
Study 2938551 — intervention group
Group type: COMPARATOR
Intervention: Implantable pump and resection (Group B)
Number of subjects: 27
Study 2938551 — intervention group
Group type: COMPARATOR
Intervention: Implantable pump and arterial embolization and portal vein branch ligation (Group C)
Number of subjects: 27
Study 2938551 — intervention group
Group type: COMPARATOR
Intervention: Implantable pump, partial resection, arterial embolization, and portal vein branch ligation (Group D)
Number of subjects: 27
Study 28674856 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine-timolol (FCBT)
Number of subjects: 257
Study 28674856 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide-timolol (FCBZT)
Number of subjects: 257